ES476496A1 - Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. - Google Patents

Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.

Info

Publication number
ES476496A1
ES476496A1 ES476496A ES476496A ES476496A1 ES 476496 A1 ES476496 A1 ES 476496A1 ES 476496 A ES476496 A ES 476496A ES 476496 A ES476496 A ES 476496A ES 476496 A1 ES476496 A1 ES 476496A1
Authority
ES
Spain
Prior art keywords
formula
radical
compound
hydrogen
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES476496A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES476496A1 publication Critical patent/ES476496A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES476496A 1977-12-29 1978-12-29 Procedimiento para preparar derivados de acido ftalazin-4- ilacetico. Expired ES476496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5414277 1977-12-29

Publications (1)

Publication Number Publication Date
ES476496A1 true ES476496A1 (es) 1979-04-16

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES476496A Expired ES476496A1 (es) 1977-12-29 1978-12-29 Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.

Country Status (31)

Country Link
US (2) US4251528A (OSRAM)
EP (1) EP0002895B1 (OSRAM)
JP (2) JPS5495582A (OSRAM)
AT (1) AT365581B (OSRAM)
AU (1) AU516264B2 (OSRAM)
BG (1) BG34336A3 (OSRAM)
CA (1) CA1107732A (OSRAM)
CS (1) CS241015B2 (OSRAM)
CY (1) CY1219A (OSRAM)
DD (1) DD141021A5 (OSRAM)
DE (1) DE2861170D1 (OSRAM)
DK (1) DK151253C (OSRAM)
ES (1) ES476496A1 (OSRAM)
FI (1) FI64357C (OSRAM)
GR (1) GR65303B (OSRAM)
HK (1) HK22484A (OSRAM)
HU (1) HU182585B (OSRAM)
IE (1) IE47592B1 (OSRAM)
IL (1) IL56099A0 (OSRAM)
IN (1) IN150196B (OSRAM)
IT (1) IT1110885B (OSRAM)
MY (1) MY8500359A (OSRAM)
NO (1) NO154346C (OSRAM)
NZ (1) NZ189034A (OSRAM)
PH (1) PH15435A (OSRAM)
PL (1) PL118443B1 (OSRAM)
PT (1) PT68956A (OSRAM)
SG (1) SG68683G (OSRAM)
SU (3) SU1087075A3 (OSRAM)
YU (3) YU41607B (OSRAM)
ZW (1) ZW24978A1 (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5011840A (en) * 1986-11-24 1991-04-30 Pfizer Inc. Imidazolidinedione derivatives in diabetes treatment
GB8704569D0 (en) 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0315249A1 (en) * 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) * 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク. 糖尿病の合併症を制御する置換ピリミジン類
CA2147504A1 (en) * 1992-11-02 1994-05-11 Prasun K. Chakravarty Substituted phthalazinones as neurotensin antagonists
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
JPH09506068A (ja) * 1993-07-26 1997-06-17 藤沢薬品工業株式会社 悪液質治療のためのオキソフタラジン類
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
WO1998042324A2 (en) * 1997-03-21 1998-10-01 The Regents Of The University Of California Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
ATE502041T1 (de) * 1997-04-15 2011-04-15 Csir Nicht-therapeutische methode zur appetitunterdrückung
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
CA2430309A1 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
ATE297902T1 (de) 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
SI1373259T1 (en) 2001-03-30 2005-04-30 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
PL367112A1 (en) * 2001-04-30 2005-02-21 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
WO2003092696A1 (en) * 2002-04-30 2003-11-13 Novartis Ag Method for decreasing capillary permeability in the retina
MXPA05001011A (es) * 2002-07-26 2005-06-08 Inst For Pharm Discovery Inc Derivado de acidos indolalcanoicos substituidos y formulaciones que lo contienen para uso en tratamiento de complicaciones diabeticas.
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
MX393754B (es) * 2012-12-14 2025-03-24 Phusis Therapeutics Inc Metodos y composiciones para inhibir cnksr1
WO2016172191A1 (en) 2015-04-20 2016-10-27 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting cnksr1
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
KR102857329B1 (ko) * 2018-10-04 2025-09-10 닛토덴코 가부시키가이샤 내열 이형 시트 및 열 압착 방법
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (OSRAM) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
CY1219A (en) 1984-04-06
EP0002895A1 (en) 1979-07-11
IT1110885B (it) 1986-01-06
SU1272984A3 (ru) 1986-11-23
DK151253B (da) 1987-11-16
YU42807B (en) 1988-12-31
US4251528A (en) 1981-02-17
ZW24978A1 (en) 1980-10-22
YU232082A (en) 1983-01-21
PL118443B1 (en) 1981-10-31
NZ189034A (en) 1981-11-19
EP0002895B1 (en) 1981-10-14
DE2861170D1 (en) 1981-12-24
FI64357C (fi) 1983-11-10
SU1072803A3 (ru) 1984-02-07
FI783844A7 (fi) 1979-06-30
IL56099A0 (en) 1979-01-31
AU516264B2 (en) 1981-05-28
NO154346C (no) 1986-09-03
YU41607B (en) 1987-12-31
JPH0262532B2 (OSRAM) 1990-12-26
AU4204078A (en) 1979-07-05
PT68956A (en) 1979-01-01
PH15435A (en) 1983-01-18
BG34336A3 (bg) 1983-08-15
CS241015B2 (en) 1986-03-13
NO784397L (no) 1979-07-02
NO154346B (no) 1986-05-26
DK541878A (da) 1979-06-30
IE782337L (en) 1979-06-29
YU232182A (en) 1983-01-21
YU312778A (en) 1983-01-21
DD141021A5 (de) 1980-04-09
GR65303B (en) 1980-08-01
ATA937678A (de) 1981-06-15
HK22484A (en) 1984-03-23
HU182585B (en) 1984-02-28
JPS6326110B2 (OSRAM) 1988-05-27
IN150196B (OSRAM) 1982-08-14
JPS63119469A (ja) 1988-05-24
IE47592B1 (en) 1984-05-02
SU1087075A3 (ru) 1984-04-15
US4393062A (en) 1983-07-12
CA1107732A (en) 1981-08-25
JPS5495582A (en) 1979-07-28
IT7852480A0 (it) 1978-12-28
DK151253C (da) 1988-05-16
MY8500359A (en) 1985-12-31
FI64357B (fi) 1983-07-29
SG68683G (en) 1984-08-03
AT365581B (de) 1982-01-25
YU42054B (en) 1988-04-30

Similar Documents

Publication Publication Date Title
ES476496A1 (es) Procedimiento para preparar derivados de acido ftalazin-4- ilacetico.
ES477695A1 (es) Un procedimiento para preparar derivados de deshidrociclici-minoacidos.
SE7603931L (sv) Forfarande for framstellning av nya tetracykliska foreningar
ES8601924A1 (es) Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.
ES485274A1 (es) Un procedimiento para la preparacion de derivados de fenil- piperacina
ES8201116A1 (es) Procedimiento para preparar derivados de 2-nitro-5-(fenoxi sustituido)-benzoilo
WO1979001114A1 (fr) Dialkyl 4-methylphosphinobutyrates et leur procede de fabrication
GB1461173A (en) Preparation of 3- 4-or 5-substituted thiazol-2-oxy- propanediol 1,2-acetonides
ES2060250T3 (es) Procedimiento para producir beta-caroteno y compuestos intermedios utiles para el procedimiento.
AU568064B2 (en) 4-acylamino-1-aza-adamantanes
JPS5581846A (en) Novel 2*4*66triiodooisophthalamic acid derivative*its manufacture and x ray contrast agent containing it
ES8401761A1 (es) Un procedimiento para la preparacion de derivados de 1-(3,4,5-trimetoxicinamoil)-4-aminocarboniletil-piperazina sustituidos.
ES8301888A1 (es) "procedimiento para la preparacion de derivados de fenoxi-aminopropanol substituidos" como divisional de la patente de invencion n 502.649 del 1 junio 1981.
FR2474488B1 (OSRAM)
GB1082072A (en) Phenylsulfinylalkanoic acid derivatives
DE3261606D1 (en) Novel quinolinecarboxylic acid derivative, process for production thereof, and antibacterial agent containing said compound as active ingredient
ES459087A1 (es) Procedimiento para preparar fenilacetilenos sustituidos.
ES473834A1 (es) Procedimiento de preparacion de nuevos compuestos indolicos.
GB2004543A (en) A process for preparing phenylalkane carboxylic acids
ES8603412A1 (es) Procedimiento para la obtencion de acemetacina
ES8600188A1 (es) Procedimiento de preparacion de un derivado 1,1-difenilpropan-1-ol
JPS57159729A (en) Manufacture of trichloromethyl-substituted aromatic compounds and aromatic compounds obtained thereby
ES467513A1 (es) Un procedimiento para la preparacion de un compuesto
ES471193A1 (es) Procedimiento para la preparacion de derivados pirazolinicos
JPS5265251A (en) Synthesis of prostaglandin derivatives

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000301